Jilin Lincun Chinese Medicine Development

Jilin Lincun Chinese Medicine Development is a specialized pharmaceutical company focused on the cultivation, procurement, and primary processing of traditional Chinese medicine (TCM) materials. Established in 1988 and headquartered in Changchun, Jilin Province, the company operates as a core subsidiary of Tianjin China Medico Technology (Sheng Shi Bai Cao), which is controlled by the Japanese pharmaceutical giant Tsumura & Co. Jilin Lincun is recognized as a leading exporter of high-quality TCM ingredients, particularly ginseng, licorice, and ephedra, maintaining extensive standardized planting bases that adhere to GACP (Good Agricultural and Collection Practices) standards. The company's portfolio includes over 300 varieties of herbal decoction pieces and bulk medicinal products supplied to global markets, including Japan, South Korea, and Europe. By integrating advanced traceability systems and rigorous quality control, Jilin Lincun supports Tsumura's mission to provide safe and effective Kampo and TCM solutions worldwide. The company plays a critical role in the global supply chain for natural products, bridging traditional herbal knowledge with modern industrial standards.